Drug Trial Radar · NCT04296370
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Last checked: Nov 19, 2026Latest source record: Aug 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
474
Planned (sponsor's estimate)
Start
Jul 13, 2020
Primary completion
Jun 30, 2022
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Physicians Choice Chemotherapy, as treatment, in patients with a Germline BRCA Mutation and HER2-negative Metastatic Breast Cancer. The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 3 portion of the study.
Conditions
- Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Interventions
Fluzoparib; ApatinibDrug
Fluzoparib Orally twice daily; Apatinib Orally once daily
FluzoparibDrug
Fluzoparib Orally twice daily
Physician's choice chemotherapyDrug
Investigators will declare one of the following regimens: Capecitabine Vinorelbine
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Safety Lead-in) dose limited toxicity (DLT)Time frame: up to 21 days
- (Safety Lead-in) Recommended Phase II Dose (RP2D)Time frame: up to 21 days
- (Phase 3) Progression free survival(PFS) in HER2-negative Metastatic Breast Cancer patientsTime frame: Radiological scans performed at baseline then every ~6 weeks up to 30 weeks, then every ~ 9 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu HengRui Medicine Co., Ltd.
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.